You will be redirected to the website of our parent company, Schönherr Rechtsanwälte GmbH: www.schoenherr.eu
Schoenherr's healthcare group draws on a breadth of experience across the firm's practice areas. We combine specialist knowledge and experience with the insights and track-record of our market-leading transactional practice.
Our healthcare & life sciences team covers a wide range of subjects, including pharmaceuticals, biochemistry, chemicals, e-health, cosmetics, medical devices, toys, tobacco products, food and feed.
Partners Andreas Natterer and Paweł Halwa lead and coordinate the Schoenherr expert team. We act for and advise all stakeholders active in the healthcare, life sciences, biotech and pharma sectors. Areas of particular expertise are regulatory life sciences work and transactional advice regarding targets in the healthcare and life sciences industry.
Working closely and in integrated teams with specialists in:
Our full-service offering in the healthcare & life sciences sector covers:
Our advisory covers inter alia:
AI chatbots: Fido in Poland
Artificial intelligence (AI) is entering the medical sector more and more boldly, transforming the healthcare system and changing the way patients and doctors communicate and how the process of caring for patients' health looks. One of the most exciting tools of this revolution are medical chatbots – AI-based programmes that support both patients and professionals by automating many tasks and offering personalised assistance.
03 July 2025
austria bulgaria poland czech republic romania
S.Rosenthaler A.Natterer M.Voldánová M.Demirev H.Hadzhiiliev E.Todorova A.Minioti D.Rutecka P.Podsiedlik P.Klimek-Woźniak O.Grecu I.Sava
to the point: Healthcare & Life Sciences Q2/2025
Welcome to the very first edition of to the point: Healthcare & Life Sciences – a new format designed to keep you informed about legal and regulatory developments shaping the sector across Europe.
Pharmaceuticals: challenges in entering Bulgaria's wholesale medicinal market
The pharmaceutical market in Bulgaria is a dynamic and rapidly growing sector, driven by increasing healthcare demands and a robust regulatory framework. It features a competitive mix of local and international players, with a significant presence of generic and innovative medicinal products. The push for generic medicinal products has also led to a rise in previously limited patent-related cases and revocation proceedings. However, the wholesale market remains crucial for ensuring the availability and distribution of medicinal products throughout the country.
The coronavirus presents us with completely new challenges. With the coronavirus info corner we aim to provide specifics about certain legal aspects surrounding Covid-19.
Schoenherr's healthcare & life sciences team consists of experienced lawyers across all our CEE offices.